-
1.发明申请Methods and Kits for Predicting Treatment Response in Type II Diabetes Mellitus Patients 审中-公开预测II型糖尿病患者治疗反应的方法和试剂盒公开(公告)号：US20100273661A1
公开(公告)日：2010-10-28
申请号：US12663311
申请日：2008-06-11
申请人： Yang Qiu , Dilip Rajagopalan , Lei Zhu , Susan C Connor , Guanghui Hu , David Maclean , Doris Damian , Amir Handzel , Rajalakshmi Balasubramanian
发明人： Yang Qiu , Dilip Rajagopalan , Lei Zhu , Susan C Connor , Guanghui Hu , David Maclean , Doris Damian , Amir Handzel , Rajalakshmi Balasubramanian
IPC分类号： G01N33/92 , G01N33/68 , G01N33/48 , C12Q1/37 , G01N33/66 , G01N33/72 , C40B30/00 , G06F19/00 , A61B5/00
CPC分类号： G01N33/6893 , G01N2333/54 , G01N2800/042 , G06Q50/24 , G16B40/00 , Y10T436/143333 , Y10T436/144444 , Y10T436/201666 , Y10T436/203332
摘要： A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine. Also provided are kits useful for the methods of the invention.
摘要翻译： 提供了预测II型糖尿病患者对罗格列酮治疗反应的方法。 该方法涉及来自患有II型糖尿病的患者的至少一种样品，并分析预测将对罗格列酮治疗作出反应的患者的生物标志物。 生物标志物至少包括白细胞介素-8，组氨酸，柠檬酸盐。 这些生物标志物在至少一种选自基于多数投票的分类器和支持向量机（SVM）分类器的分类分析中被鉴定。 还提供了用于在开始治疗后8周预测II型糖尿病患者对格列本脲的治疗反应的方法。 该方法包括从已经用格列本脲治疗约4周的II型糖尿病患者获得样品，并分析预测在8周时对格列本脲治疗作出反应的患者的生物标志物。 在该方法中有用的生物标志物至少包括鞘磷脂23：1和L-苯丙氨酸。 还提供了可用于本发明方法的试剂盒。
-
公开(公告)号：US08206986B2
公开(公告)日：2012-06-26
申请号：US11918078
申请日：2006-03-13
申请人： Doris Damian , Amir Handzel , Aram Adourian
发明人： Doris Damian , Amir Handzel , Aram Adourian
CPC分类号： G01N33/6896
摘要： Markers are provided that are predictive of Alzheimer's disease. Levels of these markers, when different from a standard, are indicative of a patient being at risk of having or developing Alzheimer's disease.
摘要翻译： 提供了预测阿尔茨海默病的标记物。 当与标准物不同时，这些标记物的水平指示患有患有或发展阿尔茨海默病的风险的患者。
-
公开(公告)号：US08321154B2
公开(公告)日：2012-11-27
申请号：US12593149
申请日：2008-03-24
申请人： Aram S. Adourian , Doris Damian , Amir Handzel
发明人： Aram S. Adourian , Doris Damian , Amir Handzel
CPC分类号： G01N33/6893 , G01N33/92 , G01N2405/04 , G01N2800/324 , Y10T436/144444 , Y10T436/147777 , Y10T436/173845 , Y10T436/200833 , Y10T436/201666
摘要： Markers are provided for detecting coronary artery disease. Levels of these markers are indicative of a patient being at risk of having or developing coronary artery disease.
摘要翻译： 标记用于检测冠状动脉疾病。 这些标记物的水平表示患有患冠状动脉疾病或发展成冠状动脉疾病的风险的患者。
-
公开(公告)号：US20100173346A1
公开(公告)日：2010-07-08
申请号：US12593149
申请日：2008-03-24
申请人： Aram Adourian , Doris Damian , Amir Handzel
发明人： Aram Adourian , Doris Damian , Amir Handzel
CPC分类号： G01N33/6893 , G01N33/92 , G01N2405/04 , G01N2800/324 , Y10T436/144444 , Y10T436/147777 , Y10T436/173845 , Y10T436/200833 , Y10T436/201666
摘要： Markers are provided for detecting coronary artery disease. Levels of these markers are indicative of a patient being at risk of having or developing coronary artery disease.
摘要翻译： 标记用于检测冠状动脉疾病。 这些标记物的水平表示患有患冠状动脉疾病或发展成冠状动脉疾病的风险的患者。
-
公开(公告)号：US20090211346A1
公开(公告)日：2009-08-27
申请号：US11918078
申请日：2006-03-13
申请人： Doris Damian , Amir Handzel , Aram Adourian
发明人： Doris Damian , Amir Handzel , Aram Adourian
IPC分类号： G01N30/68
CPC分类号： G01N33/6896
摘要： Markers are provided that are predictive of Alzheimer's disease. Levels of these markers, when different from a standard, are indicative of a patient being at risk of having or developing Alzheimer's disease.
摘要翻译： 提供了预测阿尔茨海默病的标记物。 当与标准物不同时，这些标记物的水平指示患有患有或发展阿尔茨海默病的风险的患者。
-
公开(公告)号：US20110010099A1
公开(公告)日：2011-01-13
申请号：US11992257
申请日：2006-09-19
申请人： Aram S Adourian , Matej Oresic , Doris Damian , Eric K. Neumann , Thomas Plasterer , Ezra Jennings
发明人： Aram S Adourian , Matej Oresic , Doris Damian , Eric K. Neumann , Thomas Plasterer , Ezra Jennings
CPC分类号： G16B5/00
摘要： The present teachings relate to gaining insight into biological states, e.g., disease states or drugged states, by gathering, integrating, and combining biomolecular data. More particularly, the present teachings relate to methods and systems for profiling a state of a biological system, finding accessible biomarkers representative of the state of a biological system, and deriving insights into the biochemistry of a biological system for therapeutic, diagnostic, prognostic and other purposes.
摘要翻译： 本教导涉及通过收集，整合和组合生物分子数据来了解生物状态，例如疾病状态或药物状态。 更具体地，本教导涉及用于分析生物系统的状态，找到代表生物系统的状态的可及性生物标志物的方法和系统，以及用于治疗，诊断，预后等的生物系统的生物化学的见解 目的
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.035 秒)
